XOMA 213 is a first-in-class allosteric inhibitor of prolactin action; proof of mechanism has been established in clinical studies.
It is a humanized IgG1-Kappa monoclonal antibody that binds to the extracellular domain of the human prolactin receptor with high affinity at an allosteric site. The antibody has been shown to inhibit prolactin-mediated signaling, and it is potent and similarly active against several animal and human prolactin receptors.
XOMA 213 can be developed for treating certain prolactinomas, conditions of benign tumors on the pituitary gland that lead to hyperprolactinemia-induced sexual dysfunction, infertility, and osteoporosis. It could also be developed as a treatment for anti-psychotic-induced hyperprolactinemia, a side effect seen in patients treated with commonly used antipsychotics, antidepressants, and pain medications. Currently available therapies to address these side effects can worsen psychosis.
